We are pleased to announce the successful conclusion of the SENTINEL project, a groundbreaking collaboration aimed at developing an implantable sensor to monitor patients at risk of prostate cancer relapse and enabling early diagnosis. The project's final meeting took place at INL - International Iberian Nanotechnology Laboratory, in Braga, Portugal, to discuss the final results, challenges, and next steps.
The main objective of the SENTINEL project was to develop a minimally invasive and biocompatible implantable biosensor to be used in early tumor surveillance in post-operative prostate cancer patients. This biosensor incorporates star-shaped gold nanoparticles in a hydrogel, serving as a sensitive sensor to detect specific cancer markers. Said technology aims to increase the positive predictive value of cancer screening while facilitating the remote and ubiquitous wide-scale monitoring of patients.
Over the past three years, Stemmatters has been pleased to serve as the coordinator of this project, working alongside honored partners such as INL, The University of Texas at Austin (UTA), Life and Health Sciences Research Institute (ICVS), and 2CA-Braga (Clinical Academic Center - Braga). We are also grateful to the UT Austin Portugal Program, a Science and Technology joint venture between Portugal and UTA, for their support in funding this project.
As we celebrate the culmination of the SENTINEL project, we eagerly look forward to the next phase of our journey. Stemmatters remains committed to pushing the boundaries of regenerative medicine and innovative healthcare solutions, driven by our passion for making a positive impact on people's lives.
If you want to learn more, please visit the project website.